Last Updated : January 17, 2025
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
Input is information, insight, or advice given to us to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Draft Recommendations
faricimab (Vabysmo)
Therapeutic Area: Retinal vein occlusion
Draft recommendations posted for stakeholder feedback: 16 January, 2025
End of feedback period: January 31, 2025
Draft Recommendation
Open Calls for Patient and Clinician Input
Therapeutic Area
Therapeutic Area :
Crohn’s disease
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Epithelial ovarian, fallopian tube, or primary peritoneal cancer
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
atopic dermatitis
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Amyotrophic lateral sclerosis (ALS)
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Soft tissue and uterine leiomyosarcoma
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
HER2+ breast cancer
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Neuroendocrine tumours
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Advanced or metastatic breast cancer
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Mantle cell lymphoma (MCL)
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
HR-positive, HER2-negative advanced or metastatic breast cancer
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Last Updated : January 17, 2025